GLP-1 Drugs Associated With Significantly Higher Rates of Nail Problems

A large prospective study found that users of GLP-1 receptor agonists experienced nail disorders at much higher rates than non-users, with onycholysis (nail separation) occurring in 39.3% of drug users compared to 8.7% of non-users. Nail discoloration was also significantly more common in GLP-1 users, affecting 45.6% versus 17.0% of the comparison group, and other nail issues like fragility and ridging were similarly elevated. While nearly half of GLP-1 users had pre-existing nail problems, analyses adjusting for comorbidities and weight loss still showed two- to four-fold higher rates of these disorders, suggesting a possible direct drug effect.

Researchers tracked over 575 individuals using GLP-1 drugs alongside a comparison group of obese or diabetic patients not taking these medications. The investigation revealed that nail separation affected roughly 4 in 10 GLP-1 users versus 1 in 10 non-users, while discoloration struck nearly half of drug users compared to about 1 in 6 controls. Additional nail problems including brittleness and textural irregularities also appeared more frequently in the treatment group.

Importantly, even after accounting for weight loss—a known factor affecting nail health—the higher rates persisted. Researchers also found that roughly half of GLP-1 users had experienced nail issues before starting treatment, yet statistical adjustments still showed substantially elevated disorder rates during drug use, suggesting the medication itself may play a direct role rather than complications solely from rapid weight reduction.